GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock

PHASE3TerminatedINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Severe SepsisSeptic Shock
Interventions
DRUG

Immunoglobulin G

Immunoglobulin 1.5-2g/Kg/3days

Trial Locations (17)

Unknown

Korea University Ansan Hospital, Ansan

Hallym University Sacred Heart Hospital, Anyang

Chungbuk National University Hospital, Cheongju-si

Gachon University Gil Hospital, Incheon

Gyrongsang National University Hospital, Jinju-si, Gyeongsangnam-do,

Asan Medical Center, Seoul

Ewha Womans University Mokdong Hospital, Seoul

Kangdong Sacred Heart Hospital, Seoul

Kangnam Sacred Heart Hospital, Seoul

Korea University Anam Hospital, Seoul

Korea University Guro Hospital, Seoul

Samsung Medical Center, Seoul

Seoul Medical Center, Seoul

Severance Hospital, Seoul

The Catholic of Korea Yeouido ST. Mary's Hospital, Seoul

Ajuo University Hospital, Suwon

Wonju Christian Hospital, Wŏnju

Sponsors
All Listed Sponsors
collaborator

Symyoo

INDUSTRY

lead

Green Cross Corporation

INDUSTRY

NCT01315496 - GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock | Biotech Hunter | Biotech Hunter